82 completed, 18 withdrawn, 17 unknown, 16 terminated. 42 Phase 2, 30 Not applicable, 30 Phase 4, 24 Phase 3, 19 Phase 1.
Follow Omacor: new trials by email Literature Review of Omacor trials Research Report on Omacor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-08-04 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Altering Lipids for Tolerance of Aromatase Inhibitor Therapy Omega-3 fatty acid supplement - Breast Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 77 | 2020-07-28 | 2026-05-06 |
| Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE) Multi-modal intervention - Gastric Cancer, Colorectal Cancer | Phase 2 | Unknown | Kil Yeon Lee | 112 | 2020-01-31 | 2021-06-01 |
| Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers Curcumin C3 complex®, Lovaza®, Placebo - Lung Diseases, Lung Cancer, Protection Against | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 19 | 2019-06-05 | 2026-02-27 |
| Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome | Phase 2 | Unknown | University of Kansas Medical Center | 21 | 2019-02-06 | 2023-06-01 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| Pro-Resolving Mediators in Acute Inflammation in Humans Lovaza, Cantharone, Phlebotomy - Inflammation; Skin, Resolution | Early Phase 1 | Completed | Brigham and Women's Hospital | 19 | 2018-07-02 | 2022-05-26 |
| Bioavailability of EPA + DHA in a SMEDS Formulation EPA + DHA in SMEDS Formulation, Lovaza (active comparator; already FDA approved) - Bioavailability | Not applicable | Completed | Midwest Center for Metabolic and Cardiovascular Research | 24 | 2018-02-16 | 2023-03-23 |
| Phase I Drug-drug Interaction of Omega-3 and Atorvastatin Omacor, Pritor, Omacor + Pritor - Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Unknown | DongKoo Bio & Pharma | 48 | 2018-02-01 | 2018-02-22 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy Omacor (Omega-3-acid ethyl esters) - History of Myocardial Infarction, Hypertriglyceridemia | Completed | Abbott | 3000 | 2018-01-24 | 2020-10-12 | |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2017-12-28 | 2024-05-22 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy Avelumab, Bevacizumab, Capecitabine - Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 |
Showing 20 of 138. Sign in to see all of them.
Hypertriglyceridemia (28) · Cardiovascular Diseases (9) · Breast Neoplasms (8) · Atrial Fibrillation (7) · Diabetes Mellitus (7) · Diabetes Mellitus, Type 2 (7) · Inflammation (6) · HIV Infections (5) · Hyperlipidemias (5) · Non-alcoholic Fatty Liver Disease (5) · Colorectal Neoplasms (4) · Dyslipidemias (4) · Hypercholesterolemia (4) · Insulin Resistance (4) · Obesity (4)
ImmunityBio, Inc. (11) · Brigham and Women's Hospital (8) · GlaxoSmithKline (6) · Takeda (5) · AstraZeneca (4) · Provident Clinical Research (4) · H. Lee Moffitt Cancer Center and Research Institute (3) · Massachusetts General Hospital (3) · Medical University of Vienna (3) · University of Pennsylvania (3) · Washington University School of Medicine (3) · Boston Children's Hospital (2) · Carol Fabian, MD (2) · Columbia University (2) · Milton S. Hershey Medical Center (2)
United States (89) · South Korea (7) · United Kingdom (7) · Austria (4) · Norway (4) · Canada (3) · Germany (3) · Italy (3) · Japan (3) · Russia (3) · Australia (2) · Denmark (2) · Hungary (2) · Israel (2) · Latvia (2)
Kevin C. Maki, PhD (3) · Allan Struthers, MD (2) · Associate Professor, Clinical Cell Biology and Medicine (2) · Bettina Mittendorfer, PhD (2) · Carol Fabian, MD (2) · Christine A Wanke, MD (2) · Kevin C Maki, PhD (2) · Livio Dei Cas, MD (2) · Nagi Kumar, Ph.D. (2) · Savina Nodari, MD (2) · Aaron I Vinik, MD, PhD (1) · Alex Pokov, MD (1) · Alex Polotsky, MD, MS (1)
PMID 21297494, PMID 15290734, PMID 17699247, PMID 18678300, PMID 19597368, PMID 19619690, PMID 19644030, PMID 19820283, PMID 20451686, PMID 20888102, PMID 21078810, PMID 21159787, PMID 21159789, PMID 21501117, PMID 21570522, PMID 21621252, PMID 21775113, PMID 21818149, PMID 21844082, PMID 21870979, PMID 22108152, PMID 22212377, PMID 22686415, PMID 22686416, PMID 22865498, PMID 22892157, PMID 23034965, PMID 23130134, PMID 23130172, PMID 23275364, PMID 23293330, PMID 23312053, PMID 23328126, PMID 23372745, PMID 23564916, PMID 23592752, PMID 23656980, PMID 23999452, PMID 24356795, PMID 24574355, PMID 24684774, PMID 24743428, PMID 24768457, PMID 24771090, PMID 24898834, PMID 24988179, PMID 25043514, PMID 25393536, PMID 25465932, PMID 25636157
2008 (1), 2014 (1), 2016 (1), 5UL1TR000135 (1), K23DK095913 (1), KL2TR000136 (1), P01GM095467 (1), P20RR021954 (1), P30CA046592 (1), P50HL083799 (1), R01AT011729 (1), R01CA138962 (1), R01CA160938 (1), R01DK049368 (1), R01DK061486 (1)